Trial Review

Technical difficulties have been reported by some users of the search function and is being investigated by technical staff. Thank you for your patience and apologies for any inconvenience caused.

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this information for consumers
Trial details imported from ClinicalTrials.gov

For full trial details, please see the original record at https://clinicaltrials.gov/ct2/show/NCT04919499




Registration number
NCT04919499
Ethics application status
Date submitted
8/06/2021
Date registered
9/06/2021
Date last updated
21/09/2023

Titles & IDs
Public title
A Study of BI 765128 in Patients With an Eye Condition Called Diabetic Macular Ischemia Who Have Received Laser Treatment
Scientific title
A First in Human Trial to Study Safety and Tolerability of Single Rising Intravitreal Doses (oPen Label, Non-randomized, Uncontrolled) and in Addition the Early Biological Response of mulTiple Intravitreal Doses (Double-masked, RandomIzed, Sham-controlleD) of BI 765128 in Panretinal photocoaGulation (PRP) Treated Diabetic rEtinopathy (DR) Patients With Diabetic Macular Ischemia (DMI) - the PARTRIDGE Study
Secondary ID [1] 0 0
2020-005425-87
Secondary ID [2] 0 0
1451-0001
Universal Trial Number (UTN)
Trial acronym
PARTRIDGE
Linked study record

Health condition
Health condition(s) or problem(s) studied:
Diabetic Retinopathy 0 0
Condition category
Condition code
Eye 0 0 0 0
Diseases / disorders of the eye
Metabolic and Endocrine 0 0 0 0
Diabetes
Cardiovascular 0 0 0 0
Diseases of the vasculature and circulation including the lymphatic system

Intervention/exposure
Study type
Interventional
Description of intervention(s) / exposure
Treatment: Drugs - BI 765128
Other interventions - Sham comparator

Experimental: Part A: BI 765128 low dose -

Experimental: Part A: BI 765128 medium dose -

Experimental: Part A: BI 765128 high dose -

Experimental: Part B: BI 765128 - Highest safe dose from Part A

Sham Comparator: Part B: Sham comparator -


Treatment: Drugs: BI 765128
BI 765128

Other interventions: Sham comparator
Sham comparator
Intervention code [1] 0 0
Treatment: Drugs
Intervention code [2] 0 0
Other interventions
Comparator / control treatment
Control group

Outcomes
Primary outcome [1] 0 0
Part A: Number of subjects with ocular dose limiting events (DLEs) from drug administration until day 8 (7 days after treatment)
Timepoint [1] 0 0
up to 7 days
Primary outcome [2] 0 0
Part B: Number of subjects with drug related Adverse Events (AEs) from drug administration until end of study (EOS)
Timepoint [2] 0 0
up to 20 weeks
Secondary outcome [1] 0 0
Part A: Number of subjects with drug related Adverse Events (AEs) at end of study (EOS)
Timepoint [1] 0 0
up to 14 weeks
Secondary outcome [2] 0 0
Part A: Number of subjects with any ocular Adverse Events (AEs) (eye disorders) at end of study (EOS)
Timepoint [2] 0 0
up to 14 weeks
Secondary outcome [3] 0 0
Part B: Change from baseline of the size of the foveal avascular zone (FAZ) in optical coherence tomography angiography (OCTA) at visit 5
Timepoint [3] 0 0
up to 12 weeks
Secondary outcome [4] 0 0
Part B: Change from baseline of the size of the foveal avascular zone (FAZ) in optical coherence tomography angiography (OCTA) at visit 6
Timepoint [4] 0 0
up to 16 weeks
Secondary outcome [5] 0 0
Part B: Change from baseline of the size of the foveal avascular zone (FAZ) in optical coherence tomography angiography (OCTA) at visit 7
Timepoint [5] 0 0
up to 20 weeks
Secondary outcome [6] 0 0
Part B: Change from baseline of best corrected visual acuity (BCVA) at Visit 7
Timepoint [6] 0 0
up to 20 weeks
Secondary outcome [7] 0 0
Part B: Number of subjects with any ocular Adverse Events (AEs) (eye disorders) from drug administration until end of study (EOS)
Timepoint [7] 0 0
up to 20 weeks

Eligibility
Key inclusion criteria
Part A

- Panretinal photocoagulation-treated diabetic retinopathy (DR) patients with either no
or inactive retinal neovascularization per investigator judgement in the study eye

- Male or female subjects of age = 18 years

- Evidence of diabetic macular ischemia (DMI) per investigator´s judgement, defined as
any degree of disruption of retinal vascularity in optical coherent tomography
angiography (OCTA)

- Glycosylated Hemoglobin, Type A1C (HbA1c) of = 12.0%

- Best-corrected visual acuity (VA) =75 letters (20/32) in the study eye

- Best corrected visual acuity (VA) in the non-study eye must be equal to or better than
best corrected VA in the study eye. If both eyes are eligible and have identical best
corrected VA the investigator may select the study eye.

- Women of childbearing potential (WOCBP) and men able to father a child must be ready
and able to use two methods of contraception with at least one of them being a highly
effective method of birth control per ICH M3 (R2) that result in a low failure rate of
less than 1% per year when used consistently and correctly.

- Signed and dated written informed consent in accordance with International Council for
Harmonisation-Good Clinical Practice (ICH-GCP) and local legislation prior to
admission to the trial

Part B:

- Panretinal photocoagulation-treated diabetic retinopathy (DR) patients with either no
or inactive retinal neovascularization per investigator judgement

- Male or female subjects of age = 18 years

- Presence of significant diabetic macular ischemia (DMI): Large foveal avascular zone
(FAZ) defined as those with =0.5mm2 area present on optical coherent tomography
angiography (OCTA). If FAZ is <0.5mm2 then an enlarged peri-foveal inter-capillary
space in at least 1 quadrant will be sufficient.

- Glycosylated Hemoglobin, Type A1C (HbA1c) of = 12.0%

- Best-corrected visual acuity (VA) =85 letters (20/20) in the study eye

- If both eyes are eligible, the investigator may select either eye to be the study eye.

- Women of childbearing potential (WOCBP) and men able to father a child must be ready
and able to use two methods of contraception with at least one of them being a highly
effective method of birth control per ICH M3 (R2) that result in a low failure rate of
less than 1% per year when used consistently and correctly.

- Signed and dated written informed consent in accordance with International Council for
Harmonisation-Good Clinical Practice (ICH-GCP) and local legislation prior to
admission to the trial
Minimum age
18 Years
Maximum age
No limit
Sex
Both males and females
Can healthy volunteers participate?
No
Key exclusion criteria
Part A:

- Subjects receiving intravitreal (IVT) injections for active Diabetic Macular Edema
(DME) (anti-vascular endothelial growth factor (VEGF), steroids) and macular laser in
the previous 3 months to screening in the study eye

- Subjects receiving anti-VEGF IVT injections for active diabetic retinopathy (DR) in
the previous 3 months to screening in the study eye

- Current or planned use of medications known to be toxic to the retina, lens or optic
nerve (e.g. desferoxamine, chloroquine/hydrochloroquine, chlorpromazine,
phenothiazines, tamoxifen, nicotinic acid, and ethambutol)

- Additional progressive eye disease in the study eye that could compromise best
corrected visual acuity (VA) (best corrected visual acuity (BCVA)), uncontrolled
glaucoma (intra-ocular pressure (IOP)>24), history of high myopia > 8 diopters in the
study eye. Anterior segment and vitreous abnormalities in the study eye that would
preclude adequate observation with spectral domain optical coherence tomography
(SD-OCT) and optical coherent tomography angiography (OCTA).

- Any intraocular surgery in the study eye within 3 months prior to screening

- Glaucoma tube shunts

- Aphakia or total absence of the posterior capsule. Yttrium aluminum garnet (YAG) laser
capsulotomy permitted, if completed more than 3 months prior to screening, in the
study eye

- Subjects not expected to comply with the protocol requirements or not expected to
complete the trial as scheduled (e.g. chronic alcohol or drug abuse or any other
condition that, in the investigator´s opinion, makes the subject an unreliable trial
subject) Further exclusion criteria apply

Part B:

- Diabetic Macular Edema (DME), defined as a Central Subfield Thickness (CST) = 305µm
for men and = 290 µm for women (Optovue Angiovue) in the study eye

- Subjects receiving intravitreal (IVT) injections for active DME (anti-vascular
endothelial growth factor (VEGF), steroids) and macular laser in the previous 3 months
to screening in the study eye

- Subjects receiving anti-VEGF intravitreal IVT injections for active Diabetic
Retinopathy (DR) in the previous 3 months to screening in the study eye

- Heavily lasered macula in the study eye per investigator judgement

- History of vitrectomy in the study eye

- Epiretinal membrane with extended foveal contour distortion in the study eye

- Current or planned use of medications known to be toxic to the retina, lens or optic
nerve (e.g. desferoxamine, chloroquine/hydrochloroquine, chlorpromazine,
phenothiazines, tamoxifen, nicotinic acid, and ethambutol)

- Additional eye disease in the study eye that could compromise best corrected VA
(BCVA). Significant visual field loss, uncontrolled glaucoma (IOP>24), clinically
significant diabetic maculopathy, history of ischemic optic neuropathy or retinal
vascular occlusion, symptomatic vitreomacular traction, or genetic disorders such as
retinitis pigmentosa; history of high myopia > 8 diopters in the study eye. Anterior
segment and vitreous abnormalities in the study eye that would preclude adequate
observation with SD-OCT and OCTA Further exclusion criteria apply

Study design
Purpose of the study
Treatment
Allocation to intervention
Randomised controlled trial
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Masking / blinding
Blinded (masking used)
Who is / are masked / blinded?
The people receiving the treatment/s


The people analysing the results/data
Intervention assignment
Other
Other design features
Phase
Phase 1/Phase 2
Type of endpoint/s
Statistical methods / analysis

Recruitment
Recruitment status
Completed
Data analysis
Reason for early stopping/withdrawal
Other reasons
Date of first participant enrolment
Anticipated
Actual
30/07/2021
Date of last participant enrolment
Anticipated
Actual
Date of last data collection
Anticipated
Actual
7/08/2023
Sample size
Target
Accrual to date
Final
46
Recruitment in Australia
Recruitment state(s)
SA,TAS
Recruitment hospital [1] 0 0
Adelaide Eye and Retina Centre - Adelaide
Recruitment hospital [2] 0 0
Hobart Eye Surgeons - Hobart
Recruitment postcode(s) [1] 0 0
5000 - Adelaide
Recruitment postcode(s) [2] 0 0
7008 - Hobart
Recruitment outside Australia
Country [1] 0 0
United States of America
State/province [1] 0 0
California
Country [2] 0 0
United States of America
State/province [2] 0 0
Maryland
Country [3] 0 0
United States of America
State/province [3] 0 0
Ohio
Country [4] 0 0
United States of America
State/province [4] 0 0
Pennsylvania
Country [5] 0 0
United States of America
State/province [5] 0 0
Texas
Country [6] 0 0
Latvia
State/province [6] 0 0
Riga
Country [7] 0 0
Netherlands
State/province [7] 0 0
Leiden
Country [8] 0 0
Spain
State/province [8] 0 0
Barcelona
Country [9] 0 0
Spain
State/province [9] 0 0
Madrid
Country [10] 0 0
Spain
State/province [10] 0 0
Zaragoza
Country [11] 0 0
United Kingdom
State/province [11] 0 0
Bristol
Country [12] 0 0
United Kingdom
State/province [12] 0 0
Liverpool
Country [13] 0 0
United Kingdom
State/province [13] 0 0
London
Country [14] 0 0
United Kingdom
State/province [14] 0 0
Oxford
Country [15] 0 0
United Kingdom
State/province [15] 0 0
Sunderland

Funding & Sponsors
Primary sponsor type
Commercial sector/Industry
Name
Boehringer Ingelheim
Address
Country

Ethics approval
Ethics application status

Summary
Brief summary
This study is open to adults with diabetic macular ischemia who have received laser
treatment. The main purpose of this study is to find out whether people with diabetic macular
ischemia can tolerate a medicine called BI 765128.

In this study, BI 765128 is given to people for the first time.

The study has 2 parts. Part A tests 3 doses of BI 765128. Participants get either a low,
medium or high dose of BI 765128 as a single injection into the eye. If participants tolerate
it well, the highest dose will be used in part B.

In part B, participants are put into 2 groups randomly, which means by chance. 1 group gets
BI 765128 as injection into the eye. The other group gets sham injections. A sham injection
means that it is not a real injection and contains no medicine. Participants cannot tell
whether they get the real injection or a sham injection. In this part, participants receive
study treatment once every month for 3 months.

Participants in part A are in the study for about 4 months and visit the study site about 8
times.

Participants in part B are in the study for about 5 months and visit the study site about 7
times.

The doctors regularly check participants' health and take note of any unwanted effects.
Trial website
https://clinicaltrials.gov/ct2/show/NCT04919499
Trial related presentations / publications
Public notes

Contacts
Principal investigator
Name 0 0
Address 0 0
Country 0 0
Phone 0 0
Fax 0 0
Email 0 0
Contact person for public queries
Name 0 0
Address 0 0
Country 0 0
Phone 0 0
Fax 0 0
Email 0 0
Contact person for scientific queries